Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo - Quiz - MDSpire

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

  • By

  • Yang Yu

  • Liang Zhan

  • Zhenzhen Tang

  • June 5, 2026

  • 0 min

Share

Original Source(s)

Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

  • by Yang Yu, Liang Zhan, Zhenzhen Tang

  • June 5, 2026

Related Content

Mortality trends from colorectal pathologies in the United States (1999–2020): a retrospective cohort study using CDC WONDER

Evaluation of 5-Aminosalicylic Acid Utilization in Crohn’s Disease Management: Insights from a Nationwide Survey of Inflammatory Bowel Disease Specialists

GLP-1 and GLP-2 as intestinal reparative therapies in inflammatory bowel disease: mechanisms, translation, and clinical opportunity